BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction 2017;112:1290-9. [PMID: 28107585 DOI: 10.1111/add.13764] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Moorman JP, Krolikowski MR, Mathis SM, Pack RP. HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia. Curr HIV/AIDS Rep 2018;15:308-14. [PMID: 29931466 DOI: 10.1007/s11904-018-0404-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 2019;16:32. [PMID: 31072401 DOI: 10.1186/s12954-019-0303-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Selfridge M, Barnett T, Lundgren K, Guarasci K, Milne R, Drost A, Fraser C. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada. Public Health Nurs 2022. [PMID: 35537120 DOI: 10.1111/phn.13092] [Reference Citation Analysis]
4 Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am 2018;32:395-405. [PMID: 29778262 DOI: 10.1016/j.idc.2018.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gicquelais RE, Foxman B, Coyle J, Eisenberg MC. Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics 2019;27:86-95. [PMID: 30930214 DOI: 10.1016/j.epidem.2019.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
8 Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S. Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis. Ann Gastroenterol 2018;31:598-603. [PMID: 30174397 DOI: 10.20524/aog.2018.0293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Hickman M, Grebely J, Bruneau J, Coffin P, Degenhardt L, Hutchinson S, Larney S, Martin N, Treloar C, Vickerman P. New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series. Addiction 2017;112:1126-7. [PMID: 28586551 DOI: 10.1111/add.13847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Stocks T, Martin LJ, Kühlmann-Berenzon S, Britton T. Dynamic modeling of hepatitis C transmission among people who inject drugs. Epidemics 2019;30:100378. [PMID: 31864130 DOI: 10.1016/j.epidem.2019.100378] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs? Int J Drug Policy 2019;72:69-76. [PMID: 31010749 DOI: 10.1016/j.drugpo.2019.04.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
12 Gountas I, Nikolopoulos G, Touloumi G, Fotiou A, Souliotis K. Could the 2010 HIV outbreak in Athens, Greece have been prevented? A mathematical modeling study. PLoS One 2021;16:e0258267. [PMID: 34618836 DOI: 10.1371/journal.pone.0258267] [Reference Citation Analysis]
13 Patel EU, Solomon SS, Mcfall AM, Srikrishnan AK, Pradeep A, Nandagopal P, Laeyendecker O, Tobian AAR, Thomas DL, Sulkowski MS, Kumar MS, Mehta SH. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. Int J Drug Policy 2018;57:51-60. [PMID: 29679811 DOI: 10.1016/j.drugpo.2018.03.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. J Theor Biol 2019;481:194-201. [PMID: 30452959 DOI: 10.1016/j.jtbi.2018.11.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
15 Dore GJ. Commentary on Gountas et al. (2017): Time to focus on empirical evidence for HCV treatment as prevention. Addiction 2017;112:1300-1. [PMID: 28586555 DOI: 10.1111/add.13796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Lombardi A, Mondelli MU; ESCMID Study Group for Viral Hepatitis (ESGVH). Hepatitis C: Is eradication possible? Liver Int 2019;39:416-26. [DOI: 10.1111/liv.14011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
17 Marquez LK, Cepeda JA, Bórquez A, Strathdee SA, Gonzalez-Zúñiga PE, Fleiz C, Rafful C, Garfein RS, Kiene SM, Brodine S, Martin NK. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Int J Drug Policy 2021;88:102710. [PMID: 32165050 DOI: 10.1016/j.drugpo.2020.102710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Høj SB, Minoyan N, Artenie AA, Grebely J, Bruneau J. The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? CanLivJ 2018;1:4-13. [DOI: 10.3138/canlivj.1.2.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Crowley D, Cullen W, Lambert JS, Van Hout MC. Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care. PLoS One 2019;14:e0222186. [PMID: 31509571 DOI: 10.1371/journal.pone.0222186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
20 Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393:1319-1329. [PMID: 30704789 DOI: 10.1016/s0140-6736(18)32277-3] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 38.7] [Reference Citation Analysis]
21 Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc 2018;21 Suppl 2:e25062. [PMID: 29633560 DOI: 10.1002/jia2.25062] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
22 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
23 Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, Priscott E, Dore GJ, Russell DB. Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clin Infect Dis. 2018;67:460-463. [PMID: 29538639 DOI: 10.1093/cid/ciy210] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
24 Gountas I, Sypsa V, Papatheodoridis G, Paraskevis D, Kalamitsis G, Anagnostou O, Antaraki A, Fotiou A, Hatzakis A. A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study. J Viral Hepat 2019;26:1311-7. [PMID: 31322302 DOI: 10.1111/jvh.13178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
26 Stone J, Fraser H, Young AM, Havens JR, Vickerman P. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. Int J Drug Policy 2021;88:102707. [PMID: 32151496 DOI: 10.1016/j.drugpo.2020.102707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gountas I, Hatzakis A, Nikolopoulos G, Touloumi G, Souliotis K. The cost of a late-detected outbreak among people who inject drugs. A modeling study. Int J Drug Policy 2021;88:103032. [PMID: 33212371 DOI: 10.1016/j.drugpo.2020.103032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Perazzo H, Luz PM. Liver disease and healthy life-expectancy with HIV. Lancet HIV 2017;4:e236-7. [PMID: 28262573 DOI: 10.1016/S2352-3018(17)30030-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
29 Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, Dalekos GN. Aiming towards hepatitis C virus elimination in Greece. Ann Gastroenterol. 2019;32:321-329. [PMID: 31263353 DOI: 10.20524/aog.2019.0375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]